The role of cyclin D1 and vascular endothelial growth factor (VEGF) in radiotherapy response of undifferentiated nasopharyngeal carcinoma

Abstract

Nasopharyngeal carcinoma (NPC) has a high incidence and mortality rate in Southeast Asia included in Indonesia. Radioresistance is a major obstacle for a successful treatment of NPC. DNA repair in the cell cycle and angiogenesis factors affect the response of tumor cells to radiotherapy. Cyclin D1 that functions in the cell cycle process and vascular endothelial growth factor (VEGF) as an angiogenesis factor are considered to play a role in the occurrence of radioresistance. The objective of this study was to evaluate the association between cyclin D1 and VEGF expressions with radiotherapy response in undifferentiated NPC. This study used a retrospective case control analysis design. Secondary data from medical records of patients diagnosed as undifferentiated NPC who received a complete radiotherapy at the Department of Radiation Oncology, Dr. Hasan Sadikin General Hospital, Bandung. There were 44 samples divided into radiosensitive (22 samples) and radioresistant (22 samples) groups. Immunohistochemical examination of cyclin D1 and VEGF expressions was performed on paraffin blocks of patients' nasopharyngeal biopsy. Data analysis used Chi-Square test with p ≤0.05. Cyclin D1 was expressed strongly in 86.4% of the radioresistant group and 59.1% in the radiosensitive group (p<0.05), VEGF was strongly expressed in 77.3% of the radioresistant group and 54.5% in the radiosensitive group (p>0.05). In conclusion, there is significant association between cyclin D1 expression with radiotherapy response in undifferentiated NPC. However, there is no association between VEGF expression with radiotherapy response.

Upregulation of LINC01503 promotes cervical cancer progression by targeting the miR-615-3p/CCND1 axis

“…Accumulating evidence shows that CCND1 influences a plethora of biological processes associated with the pathogenesis, as well as drug resistance in human cancers [24,25]. CCND1 is therefore recognized as an oncogene in multiple cancer types consisting of lung cancer, osteosarcoma, and nasopharyngeal carcinoma et al [24][25][26]. Nevertheless, the function of CCND1 in CC is unknown.…”